Al Arfaj Abdurahman Saud, Khalil Najma, Al Saleh Salman
Department of Medicine, College of Medicine, King Saud University, P.O. Box 34471, Riyadh, 11468, Saudi Arabia.
Rheumatol Int. 2009 Jul;29(9):1057-67. doi: 10.1007/s00296-009-0905-8. Epub 2009 Apr 21.
The aim of this article is to study the prevalence, clinicolaboratory features, WHO histological types, therapy and renal outcome of lupus nephritis (LN) in Saudi Arabia. During the 27-year-period (1980-2006), 299 (47.9%) cases of LN were identified among the 624 cases of systemic lupus erythematosus (SLE) follow-up at King Khalid University Hospital, Riyadh. The female:male ratio in LN was 8.3:1, with a mean age of 32 years and a mean age of onset of 23 years. The WHO renal histological types were; Class I (1%), Class II (18.1%), Class III (10%), Class IV (37.1%), Class V (11.7%), and Class VI (2.7%). Azathioprine was given to 43.1% and pulse cyclophosphamide to 65.6% in combination with other drugs. Remission was seen in 226 (75.6%) patients, renal flares in 14 (4.7%), end stage renal disease (ESRD) in 27 (9.0%), death in 18 (6.0%), and 14 (4.7%) lost follow-up. The 5- and 10-year patient survival rates in our whole LN cohort by Kaplan-Meier analysis were 96% and 95%, respectively. The survival did not differ significantly in different LN classes nor did it differ significantly during the three periods of presentation (1980-1990, 1991-2000, and 2001-2006; P > 0.05). The risk factors for poor survival were found to be older age at onset (>50-years age; P = 0.034), ESRD (P = 0.000), and low C3 (P = 0.022). The risk factors for progression to ESRD were older age at onset (>50-years age; P = 0.037), hypertension (P = 0.009), elevated serum creatinine (P = 0.000), and proliferative LN (Classes III, IV; P = 0.013, P = 0.039). Different treatment modalities did not have significant effect on survival in the whole LN cohort (P = >0.05). However, pulse cyclophosphamide favored remission in Classes II, III, IV, and V (P = 0.023). The main causes of death were renal failure (50%) and infections (44.4%).
本文旨在研究沙特阿拉伯狼疮性肾炎(LN)的患病率、临床实验室特征、世界卫生组织(WHO)组织学类型、治疗方法及肾脏转归情况。在1980年至2006年的27年期间,利雅得国王哈立德大学医院对624例系统性红斑狼疮(SLE)患者进行随访,其中确诊LN患者299例(47.9%)。LN患者中女性与男性比例为8.3:1,平均年龄32岁,平均发病年龄23岁。WHO肾脏组织学类型为:I类(1%)、II类(18.1%)、III类(10%)、IV类(37.1%)、V类(11.7%)和VI类(2.7%)。43.1%的患者使用硫唑嘌呤,65.6%的患者使用脉冲环磷酰胺并联合其他药物。226例(75.6%)患者病情缓解,14例(4.7%)出现肾脏活动,27例(9.0%)进入终末期肾病(ESRD),18例(6.0%)死亡,14例(4.7%)失访。通过Kaplan-Meier分析,整个LN队列患者的5年和10年生存率分别为96%和95%。不同LN类型患者的生存率无显著差异,在三个发病时期(1980 - 1990年、1991 - 2000年和2001 - 2006年)生存率也无显著差异(P>0.05)。生存不良的危险因素包括发病年龄较大(>50岁;P = 0.034)、ESRD(P = 0.000)和低C3(P = 0.022)。进展为ESRD的危险因素包括发病年龄较大(>50岁;P = 0.037)、高血压(P = 0.009)、血清肌酐升高(P = 0.000)和增殖性LN(III类、IV类;P = 0.013,P = 0.039)。不同治疗方式对整个LN队列患者的生存率无显著影响(P>0.05)。然而,脉冲环磷酰胺有利于II类、III类、IV类和V类患者病情缓解(P = 0.023)。主要死亡原因是肾衰竭(50%)和感染(44.4%)。